Bayer's Cancer Drug Vitraki Rejected by Both England and Germany
Healthcare watchdogs in both England and Germany officially rejected Bayer's (OTC: BAYRY) new cancer drug, Vitraki. The National Institute for Health and Care Excellence (NICE), a top English health regulator, announced on Friday it can't recommend the drug at its current price tag and said it simply isn't cost-efficient.
Germany's top drug assessment group, IQWiG, also rejected the drug, citing insufficient data. Although Bayer's drug has shown encouraging results so far, IQWiG rejected the drug because clinical trials didn't have a comparison group of people who didn't take Vitraki.
Image source: Getty Images.
Source Fool.com
